2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10274R
    Dabigatran etexilate (Standard) 211915-06-9 98%
    Dabigatran etexilate (Standard) is the analytical standard of Dabigatran etexilate. This product is intended for research and analytical applications. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
    Dabigatran etexilate (Standard)
  • HY-10309R
    Sibrafiban (Standard) 172927-65-0 98%
    Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
    Sibrafiban (Standard)
  • HY-103212
    Azepexole dihydrochloride 36067-72-8 98%
    Azepexole (B-HT 933) dihydrochloride is a potent and selective alpha 2-adrenoceptor agonist with pKis of 8.3, 7.6, and 7.5 for α2A-, α2B- and α2C-adrenoceptor subtypes, resepctively. Azepexole dihydrochloride causes concentration-dependent inhibition of peristaltic contractions (IC50= 78.72 nM).
    Azepexole dihydrochloride
  • HY-103458
    BMS 182874 hydrochloride 1215703-04-0 98%
    BMS 182874 hydrochloride is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 hydrochloride reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research.
    BMS 182874 hydrochloride
  • HY-10419A
    AH23848 hemicalcium salt 81496-19-7 98%
    AH23848 hemicalcium salt is a potent, specific and orally active thromboxane receptor blocker. AH23848 hemicalcium salt inhibits platelet deposition.
    AH23848 hemicalcium salt
  • HY-105010
    FK-739 free base 133052-30-9 98%
    FK-739 (free base) is an angiotensin II type 1 (AT1) receptor antagonist used in the study of hypertension.
    FK-739 free base
  • HY-10521R
    Darapladib (Standard) 356057-34-6 98%
    Darapladib (Standard) is the analytical standard of Darapladib. This product is intended for research and analytical applications. Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM). Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer.
    Darapladib (Standard)
  • HY-105259
    SR 43845 114037-60-4 98%
    SR 43845 is a renin inhibitor. SR 43845 decreases blood pressure and inhibits plasma renin activity. SR 43845 can be used for hypertension research.
    SR 43845
  • HY-105351
    CGS25155 150126-87-7 98%
    CGS25155 is an orally active neutral endopeptidase 24.11 (NEP 24.11) inhibitor with an IC50 of 3 nM. CGS25155 can slow down the degradation of the cardiac hormone atrial natriuretic peptide (ANP) and exhibits antihypertensive activity in the DOCA-salt induced rat hypertension model. CGS25155 can be used in cardiovascular disease research.
    CGS25155
  • HY-105392
    LB30057 184770-78-3 98%
    LB30057 (CI-1028) is an orally active selective thrombin inhibitor with an IC50 value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model.
    LB30057
  • HY-10564R
    Sarpogrelate hydrochloride (Standard) 135159-51-2 98%
    Sarpogrelate (hydrochloride) (Standard) is the analytical standard of Sarpogrelate (hydrochloride). This product is intended for research and analytical applications. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT2R antagonist, with pKis of 8.52, 6.57, and 7.43 for 5-HT2A, 5-HT2B, and 5-HT2C receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT1, 5-HT3, 5-HT4, α1-, α2- and β-adrenoreceptor, histamine H1, H2 and muscarinic M3 receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis.
    Sarpogrelate hydrochloride (Standard)
  • HY-105798
    Butanserin 87051-46-5 98%
    Butanserin (R 53393) is a potent and selective α1-adrenoceptor antagonist for the study of cardiovascular disease.
    Butanserin
  • HY-10588R
    Bay K 8644 (Standard) 71145-03-4 98%
    Bay K 8644 (Standard) is the analytical standard of Bay K 8644. This product is intended for research and analytical applications. Bay K 8644 ((±)-Bay K 8644) is a racemate consisting of two isomers (R)-(+)-Bay-K-8644 and (S)-(-)-Bay-K-8644. Bay K 8644 is a L-type Ca2+ channel agonist with an EC50 of 17.3 nM. Bay K 8644 increases Ca2+ influx through sarcolemmal Ca2+ channels by increasing the open time of the channel. Bay K 8644 has vasoconstrictive effects.
    Bay K 8644 (Standard)
  • HY-106098
    Adibendan 100510-33-6 98%
    Adibendan (BM 14478), a benzimidazole derivative, is an orally active, selective phosphodiesterase III (PDE III) activity inhibitor (IC50=2.0 μM). Adibendan has IC50 values more than 60-fold higher for the inhibition of PDE I or II. Adibendan is a new cardiotonic agent.
    Adibendan
  • HY-106124
    IS-159 133790-13-3 98%
    IS-159 is a potent serotonin 5-HT1 agonist. IS-159 has the potential for the research of migraine.
    IS-159
  • HY-106239
    Fostedil 75889-62-2 98%
    Fostedil (KB 944) is a calcium antagonist that can be used in the research of heart diseases such as angina pectoris.
    Fostedil
  • HY-10626R
    T0901317 (Standard) 293754-55-9 98%
    T0901317 (Standard) is the analytical standard of T0901317. This product is intended for research and analytical applications. T0901317 is an orally active and highly selective LXR agonist with an EC50 of 20 nM for LXRα. T0901317 activates FXR with an EC50 of 5 μM. T0901317 is RORα and RORγ dual inverse agonist with Ki values of 132 nM and 51 nM, respectively. T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice.
    T0901317 (Standard)
  • HY-106300
    AA 193 107804-48-8 98%
    AA 193 is a uricosuric agent. AA 193 increases urate excretion in hyperuricemic rats.
    AA 193
  • HY-106306
    Laprafylline 90749-32-9 98%
    Laprafylline (S 9795), a xanthine derivative, is a bronchodilator. Laprafylline has potent anti-bronchoconstrictive effects, inhibiting action on mast cell degranulation and phosphodiesterase (PDE) activity (IC50 of 6 μM).
    Laprafylline
  • HY-10655R
    Palosuran (Standard) 540769-28-6 98%
    Palosuran (Standard) is the analytical standard of Palosuran. This product is intended for research and analytical applications. Palosuran (ACT-058362) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran can improves pancreatic and renal function in diabetic rats.
    Palosuran (Standard)
Cat. No. Product Name / Synonyms Application Reactivity